Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

AZ said in the summer that anifrolumab had met its objectives in the phase 3 TULIP-2 trial, around a year after it flunked an earlier study (TULIP-1) which had caused many to dismiss any prospect ...

Anifrolumab was all-but written off in 2018 after failing the phase 3 TULIP-1 trial, but bounced back ... despite earlier reservations that its mixed clinical results might stand in the way ...

Indeed a ground-breaking successful anifrolumab study used a steroid tapering component ... novel design of prospective clinical trials in SLE, and critical teaching of the proper use of activity ...